Searchable abstracts of presentations at key conferences in endocrinology

ea0037ep805 | Pituitary: clinical | ECE2015

Pituitary apoplexy in GH-deficient adults treated with GH – a KIMS database retrospective study

Radian Serban , Jonsson Peter J , Camacho-Hubner Cecilia , Biller Beverly M K , Buchfelder Michael , AEkerblad Ann-Charlotte , Korbonits Marta

Background: Pituitary apoplexy (PitApo) has significant associated-morbidity and its management is not yet standardised.Aim: To describe prevalence and characteristics of PitApo patients in GH deficient (GHD) patients compared with two control populations.Patients and methods: Patients with ‘infarction-apoplexy’ GHD aetiology code were identified from Pfizer International Metabolic Database (KIMS). Baseline characteristic...

ea0049oc8.4 | Neuroendocrinology | ECE2017

Cerebrovascular stroke incidence in GH-treated adults: experience from KIMS (Pfizer International Metabolic Database)

Camacho-Hubner Cecilia , Cara Jose , Mattsson Anders

Background and aim: Patients with GH deficiency (GHD) have increased risk of cerebrovascular events. The aim of this study was to evaluate the rate and factors associated with the occurrence of stroke, a major cause of death and disability, in adults with GHD.Patients and methods: Data from 15,188 GHD patients treated with GH replacement therapy (GHRT) enrolled in KIMS were analyzed. Stroke incidence rates were compared to rates from the Oxford Vascular ...

ea0016p386 | Neuroendocrinology | ECE2008

Isolated GH deficiency of adult-onset in the KIMS database: prevalence, clinical presentation, and response to GH replacement

Casanueva Felipe , Abs Roger , Popovic Vera , Koltowska-Haggstrom Maria , Jonsson Bjorn , Saller Bernhard , Kourides Ione

Of the ~12 500 GH treated subjects with adult-onset GH deficiency (GHD) in KIMS (Pfizer International Metabolic Database), 3744 with multiple pituitary hormone deficiencies (MPHD) and 367 (9%) with isolated GHD (iGHD) were eligible for baseline analysis. Subjects met the following inclusion criteria: 1) never received GH prior to entry in KIMS, 2) had stimulation tests with insulin or glucagon (GH<3 μg/l), arginine (GH<0.4 μg/l), or arginine+GHRH (cut-offs ba...

ea0016p425 | Neuroendocrinology | ECE2008

Tests of growth hormone (GH) status in severe GH deficiency: do they identify a similar phenotype? Insight from the KIMS database

Toogood Andrew , Brabant George , Buchfelder Michael , Feldt-Rasmussen Ulla , Koltowska-Haggstrom Maria , Jonsson Bjorn , Krogh Rasmussen AEse , Maiter Dominique , Saller Bernhard , Biller Beverly

A GH peak of 3 μg/l during the insulin tolerance test (ITT) is considered the gold standard for identifying adults with severe GH deficiency. Alternative stimuli such as arginine (AST) and glucagon (GST) are also employed but produce lower GH peaks than the ITT in normal subjects. Despite this, 3 μg/l is used as the diagnostic threshold for these tests, raising the possibility that severe GH deficiency is being diagnosed inappropriately.We stud...

ea0016p450 | Neuroendocrinology | ECE2008

The benefit of long-term growth hormone replacement therapy in adults, results of the German KIMS database

Albrecht Christin , Buchfelder Michael , Faszbender Walter , Faust Michael , Kann Peter , Kreitschmann-Andermahr Ilonka , Kohlmann Thomas , Koltowska-Haggstrom Maria , Wallaschofski Henri

Objective: The German KIMS Database is a national surveillance study for evaluation of efficacy and safety of growth hormone (GH) replacement therapy in adults with GH deficiency (GHD) in clinical practice.Patients: The analysis was performed using data of 1425 consecutively documented adult patients (777 men, 648 women) with GHD enrolled in KIMS Germany. The present report examined baseline and long term data (>48 months, range: 48–161 month) f...

ea0007p155 | Neuroendocrinology and behaviour | BES2004

The effect of oestrogen replacement therapy (ORT) on growth hormone (GH) dose; KIMS database perspective

Mah P , Ross R , Jonsson P , Feldt-Rasmussen U , Koltowska-Haggstrom M , Webster J

Oral but not transdermal ORT reduces serum IGF-1 levels in postmenopausal women. The effect of ORT type on GH dose and sensitivity is unclear. We present a retrospective analysis of GH-deficient women on ORT in the KIMS database.AIM: To determine the type of oestrogen prescribed and its effect on GH dose.METHOD: Patients were divided into groups taking oral oestradiol valerate, conjugated oestrogen, ethinyloestradiol and transderma...

ea0049ep884 | Growth hormone IGF axis - basic | ECE2017

Safety of growth hormone replacement therapy (GHRT) in adult patients with GH deficiency: data from kims

Camacho-Hubner Cecilia , Jonsson Peter , Aydin Ferah , Rajicic Natasa , Cara Jose , Abs Roger , Hey-Hadavi Judith

Background: The efficacy of recombinant human growth hormone replacement therapy (GHRT) has been demonstrated, in part, through clinical trials conducted worldwide. KIMS (Pfizer International Metabolic Database), established in 1994 and active until 2012, includes treatment outcome data and real world safety from 15 809 patients from 31 countries.Objective: The main objective of this analysis was to evaluate the long-term safety of patients with hypopitu...

ea0022p619 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Lymphocytic hypophysitis: clinical characteristics and endocrine features of 64 GH deficient patients in KIMS: Pfizer International Metabolic Database

Bensing Sophie , Jonsson Peter , Hulting Anna-Lena , Cook David , Gordon Murray , Faust Michael , Koltowska-Haggstrom Maria , Casanueva Felipe

Objective: To characterize patients with GH deficiency associated with lymphocytic hypophysitis (LyH).Method: Patients with a diagnosis of LyH were identified in the KIMS database. The responsible clinicians were asked to confirm the diagnosis and to provide more detailed information on the patient by filling in a questionnaire.Results: One hundred and fifty patients with a diagnosis of LyH were identified in the database and 100 c...

ea0007p130 | Growth and development | BES2004

Possible factors determining individual sensitivity to GH replacement therapy; a KIMS database analysis

Monson J , Lundberg M , Bouloux P , Bevan J , Svensson J , Koltowska-Haggstrom M , Finer N

Large databases facilitate the examination of those factors, which may determine response to treatment, potentially to develop prediction models. We have used KIMS (Pfizer's international metabolic database of GH-treated adults), to examine parameters that might predict clinical response to GH therapy in hypopituitary adults.Patients/methods: Patients with non-functioning pituitary adenoma on GH titrated to maintain serum IGF-I between minus 2 and 2 SDS,...

ea0002p68 | Neuroendocrinology | SFE2001

SAFETY AND MORTALITY DURING GROWTH HORMONE (GH) REPLACEMENT THERAPY IN 4457 ADULT GH-DEFICIENT PATIENTS - A KIMS DATABASE ANALYSIS

Monson J , Abs R , #B-A|#Bengstonn|# , Feldt-Rasmussen U , Goth M , Koltowska M , Mattsson A , Westberg B , Wilton P

This analysis is based on 4457 patients (2365 males, 2092 females; mean age 44 years, range 18-83) with severe GH deficiency (GHD) enrolled in KIMS (pharmaco-epidemiological survey of GH replacement in adult GH-deficient patients, sponsored by Pharmacia Corporation). The mean duration of adult GH replacement was 2.8 years (range 0.1-11.0) giving 10,779 patient years of follow up. The baseline prevalence of diabetes mellitus prior to GH replacement was 3.7 % (compared with popu...